“ Our platform technology creates unprecedented opportunities to address previously intractable therapeutic challenges ”
In Conversation
Urs Indermühle – Managing Partner Consulting Switzerland (Non FS) and Life Sciences Sector Leader Europe West, EY
“ The combination of Switzerland's pharmaceutical excellence, our global connectivity, and advanced AI capabilities positions us to lead industry transformation initiatives that will define the next decade… ”
“ The ophthalmology sector has experienced significant capital influx following the emergence of several blockbuster treatments that demonstrated substantial commercial viability. ”
“ Public health work is an honour — we see its impact in people’s lives every day ”
“ The healthcare sector's industrial vitality directly supports our broader healthcare system objectives, creating a virtuous cycle that benefits both economic competitiveness and public health outcomes. ”
“ The Île-de-France region houses 40-50 percent of France's academic research capacity and industrial development capabilities, creating an exceptionally dense innovation landscape that requires strategic navigation. ”
“ Serious diseases often require more than one approach; cell therapy could be the missing piece [in Alzheimer's Disease] ”
“ Our strategic approach emphasises local commercial partnerships to maximise regional value creation ”
“ Culture outweighs strategy in sustaining long-term success ”
Kasper Møller – Chief Technical Officer and Executive Vice President, Europe & Japan Regions, AGC Biologics
“ Copenhagen’s role is not just about offering capacity, but about providing unique capabilities backed by the experience, resilience, and reliability that AGC Biologics has built over… ”
“ Academic institutions are increasingly responsible for the most challenging aspects of drug development—target identification, mechanism validation, and early-stage clinical translation—while pharmaceutical companies focus on later-stage clinical… ”
“ Oculis represents a global biopharma enterprise focused exclusively on ophthalmology and neuro-ophthalmology, with our organizational DNA centred on visionary innovation. ”